Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.
The Motley FoolThe company’s best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.
The company’s best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.